Long term Complete Response in Patient with Advanced, localized NSCLC with Hydrazine Sulfate, Radiation and Carboplatin, Refractory to Combination Chemotherapy.

Gold, J. Syracuse Cancer Research Institute, Syracuse, NY 13202

[Proceedings of the American Association for Cancer Research, volume 40, March 1999]

Hydrazine Sulphate (HS) has been reported to be active in patients with advanced, refractory NSCLC (JCO, 1990;8:9-15, Invest New Drugs, 1995;13:89-97) coinciding with frequent anecdotal reports of long term CR in patients treated with radiotherapy (RT) + HS. Illustrative of these reports is a 65 year old physician diagnosed in 1990 with large cell CA of the right lung and mediastinum. One month after completion of Mitomycin C, Platinol and Velban he was found to have residual disease. He was placed on Concurrent RT (6400 cGy/32 fractions, weekly Carboplatin) + HS 60mg t.i.d. 
(3 months) obtained by compassionate release from the NCI. Within 3 months he regained 40 lbs. (15 lbs. by the 5th week) and was able to return to work full time. CT scans at 3 months showed no evidence of recurrent or residual disease. Three months later he was found to have a solitary right adrenal metastasis which was resected. To date, 8 1/2 years later, he exhibits no evident disease. In view of the literature findings supporting the anticancer activity of HS (JNCI, 1998;90:1101), frequent reports of extended CR especially following combination RT+HS therapy, suggest clinical trials to confirm a possible synergy between these two modalities.

This page is designed and hosted by Next Generation Computer Systems, and is the property of the Syracuse Cancer Research Institute. © 1996, Syracuse Cancer Research Institute. All rights reserved.
Last modified on 24 August 2000 by webteam@ngen.com.